3,5-二(苯基)-1H-1,2,4-三唑 | 2039-06-7

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3,5-二(苯基)-1H-1,2,4-三唑
• 中文别名: 3,5-二苯基-1-H-1,2,4-三氮唑
• 英文名称: 3,5-diphenyl-1,2,4-triazole
• 英文别名: 3,5-diphenyl-1H-1,2,4-triazole；3,5-Diphenyl-1,2,4-triazol；3,5-Diphenyl-1H-1,2,4-triazol；3,5-Diphenyl-4H-1,2,4-triazole
• CAS: 2039-06-7
• 化学式: C₁₄H₁₁N₃
• mdl: MFCD00188356
• 分子量: 221.261
• InChiKey: KPKQWXGFEKRQQA-UHFFFAOYSA-N

物化性质

• 熔点：
  192°C
• 沸点：
  352.32°C (rough estimate)
• 密度：
  1.1882 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P501,P273,P264,P280,P337+P313,P305+P351+P338,P302+P352,P332+P313,P362
• 危险性描述：
  H315,H319,H413
• 储存条件：
  储存条件：2-8℃，干燥，密封。

反应信息

• 作为反应物：
  描述：

  3,5-二(苯基)-1H-1,2,4-三唑 在 2,4,6-三甲基苯磺酰羟胺 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 生成 1-amino-3,5-diphenyl-1,2,4-triazole
  参考文献：
  名称：

  Radical Scavenging by N -Aminoazaaromatics

  摘要：

  N-Aminoazaaromatics were found to react with nitric oxide in the presence of oxygen to afford deaminated products in high yields. The reaction proceeded almost instantaneously in various solvents including water, and one to two equivalent of NO was consumed depending upon the amount of oxygen coexisted, and 1 equivalent of N2O was released in the reaction. In addition, N-aminoazoles were deaminated by potassium superoxide to give parent azoles in good yields. Two equivalents of superoxide was consumed, and about half equivalents of both nitrite and nitrate ion were released. The results demonstrated that N-aminoazoles have ability to protect the biological system against the oxidation promoted by radicals such as nitrogen oxides and superoxide. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00118-8
• 作为产物：
  描述：

  苄脒盐酸盐 在 碘 、 caesium carbonate 作用下， 以 邻二氯苯 为溶剂， 反应 16.0h， 以78%的产率得到3,5-二(苯基)-1H-1,2,4-三唑
  参考文献：
  名称：

  I 2介导的由idine和酰亚胺形成的一锅合成1,2,4-三唑

  摘要：

  已经描述了使用I 2 / Cs 2 CO 3一锅法容易地合成3,5-二取代-1 H -1,2,4-三唑衍生物。该方法涉及容易获得的廉价试剂，并且适用于多种底物。该转化涉及高产率和高选择性的一锅顺序C–N和N–N键形成反应，并为合成3,5-二取代-1 H -1,2,4-提供了新的有用策略三唑衍生物。

  DOI：

  10.1016/j.tetlet.2016.04.015

文献信息

• Heme Oxygenase Inhibition by 2-Oxy-substituted 1-Azolyl-4-phenylbutanes: Effect of Variation of the Azole Moiety. X-Ray Crystal Structure of Human Heme Oxygenase-1 in Complex with 4-Phenyl-1-(1<i>H</i>-1,2,4-triazol-1-yl)-2-butanone
  作者：Gheorghe Roman、Mona N. Rahman、Dragic Vukomanovic、Zongchao Jia、Kanji Nakatsu、Walter A. Szarek

  DOI：10.1111/j.1747-0285.2009.00909.x

  日期：2010.1

  5‐substituted triazoles, identically 3,5‐disubstituted triazoles, 5‐substituted‐1H‐ and 5‐substituted‐2H‐tetrazoles proved to be detrimental to the inhibition of HO, with a few exceptions. The azole‐dioxolanes and the azole‐alcohols derived from the active azole‐ketones were synthesized also, but these inhibitors were less active than the corresponding imidazole‐based analogs. The first reported X‐ray crystal

  为抑制血红素加氧酶（血红素加氧酶-1和血红素加氧酶-2），设计并合成了一系列的1-偶氮基-4-苯基-2-丁酮。用其他唑类取代咪唑导致发现了新型的1 H -1,2,4-三唑和1 H-四唑类抑制剂，与咪唑类铅抑制剂等效。具有2 H-四唑或1 H的抑制剂‐1,2,3-三唑作为药效基团的效力较低。通过各种吸电子或给电子的，小的或庞大的基团，在咪唑的2或4（5）位置被单取代，或在咪唑的4和5位置相同的解离，以及用阵列代替传统的咪唑药效基团3或5取代的三唑，3,5-二取代的三唑，5取代的1 H和5取代的2 H除少数例外，四唑类被证明对HO的抑制是有害的。还合成了由活性唑酮衍生的唑二氧杂戊环酮和唑醇，但这些抑制剂的活性低于相应的基于咪唑的类似物。首次报道了人类血红素加氧酶-1与1,2,4-三唑基抑制剂（即4-苯基-1-（1 H -1,2,4-三唑-1）的复合物的X射线晶体结构yl）-2-丁酮也已确定。该抑制剂通过三唑部分中的N
• TARGETED IONOPHORE-BASED METAL DELIVERY
  申请人：The Regents of the University of California

  公开号：US20200113937A1

  公开（公告）日：2020-04-16

  The present disclosure provides ionophore compounds, which are useful for facilitating delivery of a metal ion to a cell, tissue or organ of interest. The present disclosure provides compositions comprising the subject ionophore compounds. The present disclosure provides methods of delivering a metal ion intracellularly to a target cell. The present disclosure also provides methods of treating a condition associated with a metal deficiency in an individual.

  本公开提供离子载体化合物，用于促进金属离子传递至感兴趣的细胞、组织或器官。本公开提供包含所述离子载体化合物的组合物。本公开提供将金属离子胞内传递至靶细胞的方法。本公开还提供治疗个体金属缺乏相关病症的方法。
• [EN] NOVEL ORGANIC ELECTROLUMINESCENCE COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE CONTAINING THE SAME<br/>[FR] NOUVEAUX COMPOSÉS ORGANIQUES ÉLECTROLUMINESCENTS ET DISPOSITIF ORGANIQUE ÉLECTROLUMINESCENT LES CONTENANT
  申请人：ROHM & HAAS ELECT MAT

  公开号：WO2014081206A1

  公开（公告）日：2014-05-30

  The present invention relates to a novel organic electroluminescence compound and an organic electroluminescence device comprising the same. The organic electroluminescence compound according to the present invention provides higher luminous efficiency compared with conventional materials. In addition, an OLED device using the organic electroluminescence compound according to the present invention as a light-emitting host material has lower driving voltage, which results in higher power efficiency and enhanced power consumption, and provides improved current efficiency.

  本发明涉及一种新型有机电致发光化合物和包括该化合物的有机电致发光装置。根据本发明的有机电致发光化合物与传统材料相比具有更高的发光效率。此外，使用本发明的有机电致发光化合物作为发光主体材料的OLED装置具有更低的驱动电压，从而实现更高的功率效率和增强的功耗，并提供改善的电流效率。
• NOVEL COMPOUNDS
  申请人：GRAUERT Matthias

  公开号：US20130184248A1

  公开（公告）日：2013-07-18

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R 1 , R 2 , R 3 have meanings given in the description.

  这项发明涉及到式I的化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神疾病，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。A、B、Ar、R1、R2、R3在描述中有给定的含义。
• [EN] 1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA<br/>[FR] 1,2,4-TRIAZOLES COMME MODULATEURS ALLOSTÉRIQUES DE L'ACTIVITÉ DES RÉCEPTEURS MGLU5 POUR LE TRAITEMENT DE LA SCHIZOPHRÉNIE OU DE LA DÉMENCE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013083741A1

  公开（公告）日：2013-06-13

  This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

  这项发明涉及公式（I）化合物的用途，它们作为mGlu5受体活性的正变构调节剂，包含这些化合物的药物组合物，以及使用它们作为治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍的方法，如精神分裂症或认知衰退，例如痴呆或认知障碍。A、B、X、R1、R2、R3的含义在描述中给出。

表征谱图